| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
31,570,000 |
| Market
Cap: |
19.57(M) |
| Last
Volume: |
540,567 |
Avg
Vol: |
539,079 |
| 52
Week Range: |
$0.1483 - $3.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BrainStorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; Alzheimer's disease; and other neurodegenerative diseases. NurOwn®, Co.'s proprietary platform, utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
11,500 |
11,500 |
| Total Buy Value |
$0 |
$0 |
$20,402 |
$20,402 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lebovits Chaim |
President & CEO |
• – – |
2024-05-13 |
4 |
A |
$0.49 |
$4,900 |
D/D |
10,000 |
1,099,865 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-05-11 |
4 |
A |
$0.47 |
$4,665 |
D/D |
10,000 |
1,089,865 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-05-10 |
4 |
A |
$0.47 |
$9,300 |
D/D |
20,000 |
1,079,865 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-05-07 |
4 |
A |
$0.37 |
$24,816 |
D/D |
66,300 |
1,059,865 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-05-06 |
4 |
A |
$0.38 |
$50,666 |
D/D |
135,000 |
993,565 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-04-19 |
4 |
A |
$0.52 |
$7,799 |
D/D |
15,000 |
858,565 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-04-18 |
4 |
A |
$0.53 |
$60,470 |
D/D |
115,072 |
843,565 |
|
- |
|
| Dagher Ibrahim B. |
Chief Medical OfficerOfficer |
• – – |
2024-04-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
190,000 |
|
21% |
|
| Dagher Ibrahim B. |
Chief Medical OfficerOfficer |
• – – |
2024-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
63,000 |
|
21% |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-04-17 |
4 |
A |
$0.55 |
$70,941 |
D/D |
130,000 |
728,493 |
|
- |
|
| Patlis Alla |
See Remarks |
• – – |
2024-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
65,246 |
65,246 |
|
- |
|
| Yablonka Uri |
EVP & Chief Business Officer |
• • – |
2024-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
109,426 |
126,969 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2024-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
305,198 |
598,493 |
|
- |
|
| Lindborg Stacy |
Co-Chief Executive Officer |
• – – |
2024-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
241,935 |
423,435 |
|
- |
|
| Lindborg Stacy |
Co-Chief Executive Officer |
• – – |
2023-09-01 |
4 |
B |
$1.77 |
$20,402 |
D/D |
11,500 |
181,500 |
2.74 |
-80% |
|
| Lindborg Stacy |
Co-Chief Executive Officer |
• – – |
2023-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
170,000 |
|
- |
|
| Lebovits Chaim |
President & CEO |
• – – |
2023-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
31,185 |
293,295 |
|
- |
|
| Naor Nir |
Director |
– • – |
2023-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,999 |
11,999 |
|
- |
|
| Taylor Kirk |
Chief Medical Officer |
• – – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
| Lebovits Chaim |
President & Co-CEO |
• – – |
2023-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
262,110 |
|
- |
|
| Lindborg Stacy |
Co-Chief Executive Officer |
• – – |
2023-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
135,000 |
|
- |
|
| Lindborg Stacy |
Co-Chief Executive Officer |
• – – |
2022-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
60,000 |
|
- |
|
| Lebovits Chaim |
Chief Executive Officer |
• – – |
2022-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
31,185 |
187,110 |
|
- |
|
| Kern Ralph Dr. |
COO and Chief Medical Officer |
• – – |
2022-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
35,885 |
223,310 |
|
- |
|
| Polverino Anthony J. |
Director |
– • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,882 |
25,960 |
|
- |
|
211 Records found
|
|
Page 1 of 9 |
|
|
0.05 (9.35%) 
